Laboraroty Animal Research

Korean Association for Laboratory Animal Science (한국실험동물학회)
권호 표지

Four-Week Repeated Dose Toxicity Study of a Novel HepatitisB Virus-Immunotherapeutic Agent, MBRI-98304,in Rats and Beagle Dogs

새로운 B형 간염 면역치료제 MBRI-98304의 랫드 및 비글개에 대한 4주 반복투여 독성시험

Hwang, Jae-Sik;Jang, Ho-Song;Sin, Ji-Sun;Jeong, Eun-Yong;Gang, Min-Jeong;Gwon, Yeong-Bang;Kim, Yun-Bae;Gang, Jong-Gu
황재식;장호송;신지순;정은용;강민정;권영방;김윤배;강종구

  • Published : 20020000
⟨ Previous Next ⟩

Abstract

To investigate the repeated toxicity of MBRI·98304, a novel immunotherapeutic agent against hepatitis B virus (HBV), we performed 4-week repeated dose toxicity tests in Sprague-Dawley (SD) rats and Beagle dogs. MBRI-98304 was injected subcutaneously in rats and intramuscularly in dogs everyday for 28 days at doses of 5, 50, or 500 $\mu$g/kg, respectively. No clinical signs or mortality were observed in animals treated with MBRI·98304 throughout the experimental period. Also, there were no significant changes in body weights, feed intake, water consumption, and any gross or histopathological lesions. Although, there were statistically-significant differences between the control and treated groups in urinalysis, relative and absolute organ weights, and hematological and biochemical analyses, the data were in biologically normal ranges and did not show a dose-dependent manner. Taken together, it is proposed that toxic dose levels of MBRI·98304 in both rats and dogs may be over 500 $\mu$g/kg

Keywords

References

  1. Byars NE, Nakano G, Welch M, Lehman D & Allison AC (1991): Improvement of hepatitis B vaccine by the use of a new adjuvant. Vaccine. 9(5): 309-318 https://doi.org/10.1016/0264-410X(91)90056-C
  2. Chang JS, Choi MJ, Cheong HS & Kim K (2001): Development of Thl-mediated CD8+ effector T cells by vaccination with epitope peptides encapsulated in pH-sensitive liposomes. Vaccine. 19(27): 3608-3614 https://doi.org/10.1016/S0264-410X(01)00104-9
  3. Earl FL, Melveger BE & Wilson RL (1973): The hemogram & bone marrow profile of normal neonate & weanling dogs. Lab. Anim. Sci. 23: 690-695
  4. Edmunds WJ, Medley GF, Nokes DJ, Hall AJ & Whittle HC (1993): The influence of age on the development of the hepatitis B carrier state. Proc. R Soc. Lond B Biol. Sci. 253: 197-201 https://doi.org/10.1098/rspb.1993.0102
  5. Hercas-Stubbs S, Berasain C, Golvano JJ, Lasarte JJ, Prieto I, Sarobe P, Prieto J & Borras-Cuesta F (1994): Overcoming class II-linked non-responsiveness to hepatitis B vaccine. Vaccine 12(10): 867-871 https://doi.org/10.1016/0264-410X(94)90026-4
  6. Hsu HM, Lu CF, Lee SC, Lin SR & Chen DS (1999): Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. J. Infect. Dis. 179: 360-367 https://doi.org/10.1086/513840
  7. Marques AR & Straus SE (1998): Advances in the treatment of chronic hepatitis B virus infection. Rev. Med. Virol. 8: 223-234 https://doi.org/10.1002/(SICI)1099-1654(1998100)8:4<223::AID-RMV229>3.0.CO;2-J
  8. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, Lafond R, Yuan L, Chisari FV, Furze J & Bartholomeuz R (1995): Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95(1): 341-349 https://doi.org/10.1172/JCI117662
  9. Wolford ST, Schroer RA, Gohs FX, Gallo PP, Brodeck M, Falk HB & Ruhren R (1986): Reference range data base for serum chemistry and hematology values in laboratory animals. J. Toxicol. Environm. Health. 18: 161-168 https://doi.org/10.1080/15287398609530859
  10. Yale CE & Balish E (1976): Blood and serum chemistry values of gnotobiotic Beagles. Lab. Anim. Sci. 26: 633-639
  11. 內山智晴, 常井和男, 出來俊昭 (1985): 實驗用ビ-グル犬の成長に伴 う血液學的ならぴ血淸生化學的性狀の變化. 實驗動物. 34: 367-377